According to a recent 13G filing with the US Securities and Exchange Commission Sam Isaly’s Orbimed Advisors has increased its stake in Cynapsus Therapeutics Inc. (NASDAQ:CYNA), to 1.62 million shares, which amass 13.2% of the company’s total outstanding stock. The stake compares to 1.14 million shares Orbimed Advisors disclosed in its last 13F filing for the reporting period of March 31.
Cynapsus Therapeutics is a specialty pharmaceutical company that works on developing a sublingual thin film to help the patients who suffer from Parkinson’s disease, and recently it was announced that the company has registered the last patient in its pivotal Phase 3 clinical study, which examines the effects of its sublingual thin film for the treatment of debilitating OFF states in Parkinson’s disease. Since the beginning of the year, the company’s stock is up by 6.87%. In its last quarterly financial report for the three months ended March 31, Cynapsus Therapeutics disclosed a net loss of $8.4 million and a loss per share of $0.68, which compares to a net loss of $4.1 million and a loss per share of $0.78 for the same quarter a year earlier. Recently, Janney Montgomery Scott has initiated coverage on the stock with a ‘Buy’ rating on the stock, at a price target of $24.00.
At the end of March, there were 13 investors long Cynapsus Therapeutics (NASDAQ:CYNA) from Insider Monkey’s database. Among them, the largest stake held Orbimed Advisors, and the second most valuable position was owned by Dennis Purcell’s Aisling Capital, worth around $12.2 million. Some other hedge funds with similar optimism encompass Jacob Gottlieb’s Visium Asset Management, Phill Gross and Robert Atchinson’s Adage Capital Management and Israel Englander’s Millennium Management.
On the other hand, investors who lost interest in Cynapsus Therapeutics (NASDAQ:CYNA) and sold off their positions include Kevin Kotler’s Broadfin Capital, which dumped the biggest stake valued at close to $8.9 million in stock, and D. E. Shaw’s D. E. Shaw, which dumped its stock, about $0.2 million worth.
You can access the original SEC filing by clicking here.
Ownership Summary Table
Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
---|---|---|---|---|---|---|
OrbiMed Capital GP V | 0 | 1,620,325 | 0 | 1,620,325 | 1,620,325 | 13.2% |
OrbiMed Advisors | 0 | 1,620,325 | 0 | 1,620,325 | 1,620,325 | 13.2% |
Samuel D. Isaly | 0 | 1,620,325 | 0 | 1,620,325 | 1,620,325 | 13.2% |
Follow Sam Isaly's OrbiMed Advisors
Page 1 of 7 – SEC Filing
Cynapsus Therapeutics Inc. |
(Name of Issuer) |
Common Stock |
(Title of Class of Securities) |
23257Y859 |
(CUSIP Number) |
July 6, 2016 |
(Date of Event Which Requires Filing of this Statement) |
Follow Cynapsus Therapeutics Inc.
Follow Cynapsus Therapeutics Inc.
Page 2 of 7 – SEC Filing
CUSIP No. 23257Y859 | SCHEDULE 13G | Page 2 of 7 Pages |
1 | NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) OrbiMed Capital GP V LLC | |||
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) o (b) o | | ||
3 | SEC USE ONLY | |||
4 | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | |||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5 | SOLE VOTING POWER 0 | ||
6 | SHARED VOTING POWER 1,620,325 | |||
7 | SOLE DISPOSITIVE POWER 0 | |||
8 | SHARED DISPOSITIVE POWER 1,620,325 | |||
9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,620,325 | |||
10 | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) | o | ||
11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 13.2%(1) | |||
12 | TYPE OF REPORTING PERSON (See Instructions) OO |
Follow Cynapsus Therapeutics Inc.
Follow Cynapsus Therapeutics Inc.
Page 3 of 7 – SEC Filing
CUSIP No. 23257Y859 | SCHEDULE 13G | Page 3 of 7 Pages |
1 | NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) OrbiMed Advisors LLC | |||
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) o (b) o | | ||
3 | SEC USE ONLY | |||
4 | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | |||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5 | SOLE VOTING POWER 0 | ||
6 | SHARED VOTING POWER 1,620,325 | |||
7 | SOLE DISPOSITIVE POWER 0 | |||
8 | SHARED DISPOSITIVE POWER 1,620,325 | |||
9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,620,325 | |||
10 | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) | o | ||
11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 13.2%(1) | |||
12 | TYPE OF REPORTING PERSON (See Instructions) IA |
Follow Cynapsus Therapeutics Inc.
Follow Cynapsus Therapeutics Inc.
Page 4 of 7 – SEC Filing
CUSIP No. 23257Y859 | SCHEDULE 13G | Page 4 of 7 Pages |
1 | NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Samuel D. Isaly | |||
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) o (b) o | | ||
3 | SEC USE ONLY | |||
4 | CITIZENSHIP OR PLACE OF ORGANIZATION United States | |||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5 | SOLE VOTING POWER 0 | ||
6 | SHARED VOTING POWER 1,620,325 | |||
7 | SOLE DISPOSITIVE POWER 0 | |||
8 | SHARED DISPOSITIVE POWER 1,620,325 | |||
9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,620,325 | |||
10 | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) | o | ||
11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 13.2%(1) | |||
12 | TYPE OF REPORTING PERSON (See Instructions) IN |
Follow Cynapsus Therapeutics Inc.
Follow Cynapsus Therapeutics Inc.
Page 5 of 7 – SEC Filing
CUSIP No. 23257Y859 | SCHEDULE 13G | Page 5 of 7 Pages |
Item 1. | (a) Name of Issuer: |
| (b) Address of Issuer’s Principal Executive Offices: |
Item 2. | (a) Name of Person Filing: |
| (i) | OrbiMed Capital GP V LLC (“GP V”) |
| (ii) | OrbiMed Advisors LLC (“Advisors”) |
| (iii) | Samuel D. Isaly (“Isaly”) |
| (b) Address of Principal Business Office: |
| (c) Citizenship: |
| (d) Title of Class of Securities: |
| (e) CUSIP No.: |
Follow Cynapsus Therapeutics Inc.
Follow Cynapsus Therapeutics Inc.
Page 6 of 7 – SEC Filing
CUSIP No. 23257Y859 | SCHEDULE 13G | Page 6 of 7 Pages |
Item 4. | Ownership: |
| (a) | Amount beneficially owned: See the response(s) to Item 9 on the attached cover page(s). |
| (b) | Percent of class: See the response(s) to Item 11 on the attached cover page(s). |
| (c) | Number of shares as to which such person has: |
Item 5. | Ownership of Five Percent or Less of a Class. |
Item 6. | Ownership of More Than Five Percent on Behalf of Another Person. |
Item 7. | Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. |
Item 8. | Identification and Classification of Members of the Group. |
Item 9. | Notice of Dissolution of Group. |
Item 10. | Certification. |
Follow Cynapsus Therapeutics Inc.
Follow Cynapsus Therapeutics Inc.
Page 7 of 7 – SEC Filing
CUSIP No. 23257Y859 | SCHEDULE 13G | Page 7 of 7 Pages |
OrbiMed Capital GP V LLC | ||||
By: | OrbiMed Advisors LLC, its Managing Member | |||
By: | /s/ Samuel D. Isaly | |||
Name: | Samuel D. Isaly | |||
Title: | Managing Member | |||
OrbiMed Advisors LLC | ||||
By: | /s/ Samuel D. Isaly | |||
Name: | Samuel D. Isaly | |||
Title: | Managing Member | |||
Samuel D. Isaly | ||||
/s/ Samuel D. Isaly | ||||
Name: | Samuel D. Isaly |